Drugs · Entity Annotation Prototype (beta)

8articles mentioning drugs

25drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: OCA ×

OCA

This drug is selected. Its supporting articles are shown below.

OCA8

Articles mentioning OCA

8 articles · page 1 of 1

P29 Efficacy and safety of seladelpar in patients with primary biliary cholangitis previously treated with fibrates or obeticholic acid

gutjnl · abstract · 2025-10-06 · 4 matching annotations

80.8%

seladelpar delpar OCA ursodeoxycholic acid

…brates/OCA (total, n = 131; 83%). At month 18, among continuous seladelpar patients, 9/15 (60%) patients with prior fibrate/OCA use achiev…

P33 Outcomes with triple therapy (ursodeoxycholic acid, fibrate and obeticholic acid) for treatment of high-risk primary biliary cholangitis

gutjnl · abstract · 2025-10-06 · 4 matching annotations

76.3%

OCA-FIB fibrate UDCA Obeticholic acid FIB-OCA bezafibrate OCA primary biliary cholangitis PBC

…le therapies Fibrate therapy First (FIB-OCA) OCA therapy First (OCA-FIB) (FIB-OCA) and (OCA-FIB) Comparative p Values ALP M0 (n27) M6 (…

P34 Initial clinical response and safety of elafibranor in primary biliary cholangitis: a multi-centre pharmacist-led real-world evaluation

gutjnl · abstract · 2025-10-06 · 4 matching annotations

82.6%

elafibranor bezafibrate

…afibranor initiation. 2 (7.4%) patients continued OCA alongside elafibranor. 19 (70.4%) patients had trialled bezafibrate prior to elafibra…

P44 Combination of obeticholic acid with bezafibrate, with or without ursodeoxycholic acid, in high-risk patients with primary biliary cholangitis: a single centre experience

gutjnl · abstract · 2025-10-06 · 4 matching annotations

84.0%

Bezafibrate Obeticholic acid UDCA BZA Ursodeoxycholic acid OCA Primary biliary cholangitis Barts Health NHS Trust

…cribed Ursodeoxycholic acid (UDCA), Obeticholic acid (OCA), and Bezafibrate (BZA), has shown biochemical benefit in patients with inadequat…

P107 Early real-world experiences of elafibranor in primary biliary cholangitis (PBC)

gutjnl · abstract · 2026-06-23 · 3 matching annotations

85.3%

bezafibrate Elafibranor Ela BZF UDCA OCA

…UDCA), obeticholic acid (OCA), and amongst those switching from bezafibrate (BZF).Results From Dec 2024 to Nov 2025, 54 pts initiated Ela (…

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid

bmjopen · abstract · 2026-03-11 · 3 matching annotations

87.5%

ursodeoxycholic acid (UDCA)obeticholic acid (OCA)UDCA OCA Primary biliary cholangitis (PBC)PBC London – Riverside Research Ethics Committee

…atment approach is a step-up model, wherein first-line therapy, ursodeoxycholic acid (UDCA), is given for a minimum of 12 months before the addition of sec…

P65 Real-world experience of seladelpar among patients with primary biliary cholangitis including patients switched from obeticholic acid

gutjnl · abstract · 2026-06-23 · 2 matching annotations

83.7%

Seladelpar UDCA fenofibrate elafibranor Obeticholic acid ursodeoxycholic acid (UDCA)OCA SEL-2L OCA-switch Primary biliary cholangitis (PBC)

… was recently withdrawn from the US creating a therapeutic gap. Seladelpar (SEL), approved in 2024 in the US for patients with PBC and an …

4CPS-074 Assessment of elafibranor for the treatment of primary biliary cholangitis

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

79.3%

ELAFIBRANOR SELADELPAR OBETICHOLIC ACID ELF ursodeoxycholic acid SEL OCA UDCA primary biliary cholangitis PBC

…% CI 23.7 – 50.3)) SELADELPAR (ARR = 40.9 (95% CI 28.1 – 53.8)) ELAFIBRANOR (ARR = 47.2 (95% CI 36.4 – 57.9)) ARR = 10.2 (-6.9 ; 27,3) p = …

Browse drugs

OCA

Articles mentioning OCA